Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03977753
Other study ID # LLB-2019-02
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 17, 2020
Est. completion date March 16, 2024

Study information

Verified date October 2023
Source Labo'Life
Contact Charlotte Bolle
Phone (0)497 49 13 74
Email charlotte.bolle@labolife.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age. Conventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms. No specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus. The 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts. The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.


Description:

The study duration will be maximum 45 months with 36 months of inclusion and 9 months of follow-up. Patients aged 3 years and older who present common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana) during a visit with their dermatologist/general practitioner. The total number of patients to include will be 162. Primary objective: Comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group. Secondary objectives - Comparison of the efficacy of the treatment on the disappearance of warts at 4 months between groups. - Comparison of the efficacy of the treatment on the level of disappearance (4 levels) of warts at 4 months and 6 months (end of the treatment) between groups - Comparison of the efficacy of the treatment on the recurrence of warts 3 months after the end of treatment between groups - Compare the pain related to warts during the study between groups - Safety issues. Treatment phase: - Group n°1 = 2LVERU® JUNIOR / 2LVERU® (6 months of treatment) - Group n°2 = Placebo (6 months of treatment) Post-treatment Follow-up phase: 3 months Treatment will be considered successful if the following three criteria are met for all treated warts as described at the baseline visit: - Normal skin colour at the wart site - Normal skin texture at the wart site - Normal touch at the wart site Treatment will be considered a failure, at the end of the treatment, if at least one of the above three criteria is not met for all treated warts as described at the baseline visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 162
Est. completion date March 16, 2024
Est. primary completion date December 16, 2023
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - Patients, male or female, aged 3 years and older, - Patients with common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana), - Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study, - Signature of the Informed Consent Form by the patient (and/or parents if necessary). Exclusion Criteria: - Patients who have received any curative warts treatment in the previous 2 months prior to the study, - Patients who have received any homeopathic treatment in the previous 2 months prior to the study, - Patients under immunosuppressive treatment, - Patients having received immunotherapy or micro-immunotherapy during the last 6 months, - Patients with known lactose intolerance, - Pregnant or breastfeeding women, - Patients who participated in a clinical study in the previous 2-months period, - Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study, - Patients with severe immunodeficiency disease requiring long term treatment (*) or patients under chemotherapy or radiotherapy, - Patients under listed homeopathic or phytotherapy treatment (see protocol), - Patients addicted to or using recreational drugs, - Patient under guardianship and/or curators, (*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
2LVERU® or 2LVERU® JUNIOR
The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Placebo
The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Locations

Country Name City State
Belgium Private Practice Arlon
Belgium Clinique Saint-Luc (Bouge) Bouge
Belgium Private Practice Brussel
Belgium Private Practice Ecaussinnes-d'enghien
Belgium Private Practice Fontaine l'Êveque
Belgium Private Practice Gent
Belgium Private Practice Gozée
Belgium Private Practice Hamme-Mille
Belgium Private Practice Juprelle
Belgium Private Practice Mons
Belgium Private Practice Namur
Belgium Private Practice Namur
Belgium Private Practice Oisquercq
Belgium Private Practice Plancenoit
Belgium Private Practice Quiévrain
Belgium Private Practice Saint-Symphorien
Belgium Private Practice Seneffe
Belgium Private Practice Wavre

Sponsors (1)

Lead Sponsor Collaborator
Labo'Life

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disappearance of warts at the end of treatment (6-month visit) A wart will be considered as disappeared if the colour and texture of the skin has returned to normal and can no longer be felt to the touch. 6 months
Secondary Disappearance of warts at 4 months. 4 months
Secondary Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months 4 months
Secondary Warts recurrence at 9 months 9 months
Secondary Pain evaluation during the study by visual analogic scale and consumption of antalgic medication. Minimum value: 0 (better outcome) Maximum Value: 10 (worse outcome) 6 months
Secondary Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug. 6 months
Secondary Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 6 months 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05324904 - Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts N/A
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05592041 - Studying of Natural Constituents' Treatment of Plantar Warts Early Phase 1
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Recruiting NCT06261684 - Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial. Phase 2/Phase 3
Not yet recruiting NCT05057663 - Intralesional Treatment of Plantar Wart N/A
Recruiting NCT02151630 - Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Phase 2/Phase 3
Withdrawn NCT04823845 - Plantar Wart Treatment Using Adapalene Gel Early Phase 1
Completed NCT05588999 - Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts Phase 1
Completed NCT01536834 - Safety & Performance Study of Verruca Treatment Device N/A
Recruiting NCT05488860 - Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases N/A
Recruiting NCT05520658 - Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts N/A
Not yet recruiting NCT04654091 - Cryotherapy VS. Nitric-zinc Complex in the Treatment of Plantar Warts. N/A
Not yet recruiting NCT05599971 - Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts N/A
Not yet recruiting NCT05198180 - Treatment of Plantar Warts Phase 3
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4